Cargando…

SARS-CoV-2 Nucleocapsid Protein TR-FRET Assay Amenable to High Throughput Screening

[Image: see text] Drug development for specific antiviral agents against coronavirus disease 2019 (COVID-19) is still an unmet medical need as the pandemic continues to spread globally. Although huge efforts for drug repurposing and compound screens have been put forth, only a few compounds are in l...

Descripción completa

Detalles Bibliográficos
Autores principales: Gorshkov, Kirill, Morales Vasquez, Desarey, Chiem, Kevin, Ye, Chengjin, Nguyen Tran, Bruce, Carlos de la Torre, Juan, Moran, Thomas, Chen, Catherine Z., Martinez-Sobrido, Luis, Zheng, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8751018/
https://www.ncbi.nlm.nih.gov/pubmed/35036857
http://dx.doi.org/10.1021/acsptsci.1c00182
_version_ 1784631592813068288
author Gorshkov, Kirill
Morales Vasquez, Desarey
Chiem, Kevin
Ye, Chengjin
Nguyen Tran, Bruce
Carlos de la Torre, Juan
Moran, Thomas
Chen, Catherine Z.
Martinez-Sobrido, Luis
Zheng, Wei
author_facet Gorshkov, Kirill
Morales Vasquez, Desarey
Chiem, Kevin
Ye, Chengjin
Nguyen Tran, Bruce
Carlos de la Torre, Juan
Moran, Thomas
Chen, Catherine Z.
Martinez-Sobrido, Luis
Zheng, Wei
author_sort Gorshkov, Kirill
collection PubMed
description [Image: see text] Drug development for specific antiviral agents against coronavirus disease 2019 (COVID-19) is still an unmet medical need as the pandemic continues to spread globally. Although huge efforts for drug repurposing and compound screens have been put forth, only a few compounds are in late-stage clinical trials. New approaches and assays are needed to accelerate COVID-19 drug discovery and development. Here, we report a time-resolved fluorescence resonance energy transfer-based assay that detects the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid protein (NP) produced in infected cells. It uses two specific anti-NP monoclonal antibodies conjugated to donor and acceptor fluorophores that produce a robust ratiometric signal for high throughput screening of large compound collections. Using this assay, we measured a half maximal inhibitory concentration (IC(50)) for remdesivir of 9.3 μM against infection with SARS-CoV-2 USA/WA1/2020 (WA-1). The assay also detected SARS-CoV-2 South African (Beta, β), Brazilian/Japanese P.1 (Gamma, γ), and Californian (Epsilon, ε) variants of concern (VoC). Therefore, this homogeneous SARS-CoV-2 NP detection assay can be used for accelerating lead compound discovery for drug development and for evaluating drug efficacy against emerging SARS-CoV-2 VoC.
format Online
Article
Text
id pubmed-8751018
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-87510182022-01-11 SARS-CoV-2 Nucleocapsid Protein TR-FRET Assay Amenable to High Throughput Screening Gorshkov, Kirill Morales Vasquez, Desarey Chiem, Kevin Ye, Chengjin Nguyen Tran, Bruce Carlos de la Torre, Juan Moran, Thomas Chen, Catherine Z. Martinez-Sobrido, Luis Zheng, Wei ACS Pharmacol Transl Sci [Image: see text] Drug development for specific antiviral agents against coronavirus disease 2019 (COVID-19) is still an unmet medical need as the pandemic continues to spread globally. Although huge efforts for drug repurposing and compound screens have been put forth, only a few compounds are in late-stage clinical trials. New approaches and assays are needed to accelerate COVID-19 drug discovery and development. Here, we report a time-resolved fluorescence resonance energy transfer-based assay that detects the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid protein (NP) produced in infected cells. It uses two specific anti-NP monoclonal antibodies conjugated to donor and acceptor fluorophores that produce a robust ratiometric signal for high throughput screening of large compound collections. Using this assay, we measured a half maximal inhibitory concentration (IC(50)) for remdesivir of 9.3 μM against infection with SARS-CoV-2 USA/WA1/2020 (WA-1). The assay also detected SARS-CoV-2 South African (Beta, β), Brazilian/Japanese P.1 (Gamma, γ), and Californian (Epsilon, ε) variants of concern (VoC). Therefore, this homogeneous SARS-CoV-2 NP detection assay can be used for accelerating lead compound discovery for drug development and for evaluating drug efficacy against emerging SARS-CoV-2 VoC. American Chemical Society 2022-01-03 /pmc/articles/PMC8751018/ /pubmed/35036857 http://dx.doi.org/10.1021/acsptsci.1c00182 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Gorshkov, Kirill
Morales Vasquez, Desarey
Chiem, Kevin
Ye, Chengjin
Nguyen Tran, Bruce
Carlos de la Torre, Juan
Moran, Thomas
Chen, Catherine Z.
Martinez-Sobrido, Luis
Zheng, Wei
SARS-CoV-2 Nucleocapsid Protein TR-FRET Assay Amenable to High Throughput Screening
title SARS-CoV-2 Nucleocapsid Protein TR-FRET Assay Amenable to High Throughput Screening
title_full SARS-CoV-2 Nucleocapsid Protein TR-FRET Assay Amenable to High Throughput Screening
title_fullStr SARS-CoV-2 Nucleocapsid Protein TR-FRET Assay Amenable to High Throughput Screening
title_full_unstemmed SARS-CoV-2 Nucleocapsid Protein TR-FRET Assay Amenable to High Throughput Screening
title_short SARS-CoV-2 Nucleocapsid Protein TR-FRET Assay Amenable to High Throughput Screening
title_sort sars-cov-2 nucleocapsid protein tr-fret assay amenable to high throughput screening
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8751018/
https://www.ncbi.nlm.nih.gov/pubmed/35036857
http://dx.doi.org/10.1021/acsptsci.1c00182
work_keys_str_mv AT gorshkovkirill sarscov2nucleocapsidproteintrfretassayamenabletohighthroughputscreening
AT moralesvasquezdesarey sarscov2nucleocapsidproteintrfretassayamenabletohighthroughputscreening
AT chiemkevin sarscov2nucleocapsidproteintrfretassayamenabletohighthroughputscreening
AT yechengjin sarscov2nucleocapsidproteintrfretassayamenabletohighthroughputscreening
AT nguyentranbruce sarscov2nucleocapsidproteintrfretassayamenabletohighthroughputscreening
AT carlosdelatorrejuan sarscov2nucleocapsidproteintrfretassayamenabletohighthroughputscreening
AT moranthomas sarscov2nucleocapsidproteintrfretassayamenabletohighthroughputscreening
AT chencatherinez sarscov2nucleocapsidproteintrfretassayamenabletohighthroughputscreening
AT martinezsobridoluis sarscov2nucleocapsidproteintrfretassayamenabletohighthroughputscreening
AT zhengwei sarscov2nucleocapsidproteintrfretassayamenabletohighthroughputscreening